Products Categories
    Product Certification&
    Enterprise Certification

  • Mr.Jack Shen
    Tel: +86-571-86758373

  • Mobile:
  • Tel:+86-571-86758373
  • Fax:
  • URL:http://www.huarongpharm.com
  • Province/state:Zhejiang
  • City:Hangzhou
  • Street:Room1707, 7Th Floor, Xin Chuanmei Industry Building , No.58 of Xintang Road, Jianggan District, Hangzhou, China.
  • MaxCard:
Home > Products >  Lenalidomide

Lenalidomide CAS NO.191732-72-6

  • FOB Price: USD: /Gram Get Latest Price
  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T
  • Available Specifications:

    99% (1-2)Gram99% (2-5)Gram99.9%(1-2)Gram

  • Product Details

Keywords

  • 191732-72-6
  • Lenalidomide
  • 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione,Lenalidomide

Quick Details

  • ProName: Lenalidomide
  • CasNo: 191732-72-6
  • Molecular Formula: C13H13N3O3
  • Appearance: Yellow Solid
  • Application: Used for anti-tumor, immune regulation...
  • DeliveryTime: 20 day
  • PackAge: Aluminium bag & Paper Drum
  • Port: Shanghai
  • ProductionCapacity: 500 Kilogram/Month
  • Purity: 99%
  • Storage: Normal temperature
  • Transportation: Normal condition
  • LimitNum: 1 Kilogram
  • Related Substances: Less than 1.0%
  • Residue on Ignition: Less than 0.1%
  • Heavy Metal: 20 ppm
  • Valid Period: 24 months
  • DMF: Available

Superiority

1. USDMF is available.

2. EUDMF is available.

 

Huarong Industrial Group Limited established since 2006 , has been actively developing specialty products for Finished Dosages, APIs, Intermediates, and Fine chemicals markets in North America, Europe, Korea, Japan, Mid-East and all over the World.

 

Huarong Group has a team of more than 15 professionals working with diligence and tenacity at all hours trying to make a breakthrough and leap to the industry and yours. In addition to the distribution, Huarong people have invested in Lab and cGMP plants to allows us to offer service like: develop non-infringing synthesis process(include impurity study, stability study novel polymorph forms,ect) ,technology transfer, with a view to the long-term supply to support FTF In US, EU, China and other markets.


Huarong people has built our success through the success of our clients by providing complete solutions. As our belief to be your “China Business Partner & Solution", we are looking forward to establishing a long term cooperation with our partners and clients all over the world.

Details

1. USDMF is available.

2. EUDMF is available.

 

Huarong Industrial Group Limited established since 2006 , has been actively developing specialty products for Finished Dosages, APIs, Intermediates, and Fine chemicals markets in North America, Europe, Korea, Japan, Mid-East and all over the World.

 

Huarong Group has a team of more than 15 professionals working with diligence and tenacity at all hours trying to make a breakthrough and leap to the industry and yours. In addition to the distribution, Huarong people have invested in Lab and cGMP plants to allows us to offer service like: develop non-infringing synthesis process(include impurity study, stability study novel polymorph forms,ect) ,technology transfer, with a view to the long-term supply to support FTF In US, EU, China and other markets.

 

Huarong people has built our success through the success of our clients by providing complete solutions. As our belief to be your “China Business Partner & Solution", we are looking forward to establishing a long term cooperation with our partners and clients all over the world.

 

Lenalidomide is a kind of antitumor drugs that developed by American biological pharmaceutical companies. Its chemical structure is similar with thalidomide. It has many functions such as anti-tumor, immune regulation and anti-angiogenesis. It can inhibit the secretion of inflammatory cytokines, and increase the secretion of peripheral blood mononuclear anti-inflammatory cytokines. Vitro tests show that lenalidomide can inhibit the hyperplasia of some cell lines such as namalwa cell. It can inhibit the growth of patients’ multiple myeloma cells and MM1S cell. In addition, lenalidomide also can inhibit the expression of oxidase-2 (COX-2), but it has no effect on COX-1. Two multicenter randomized double-blind placebo-controlled clinical studies evaluate the safety and curative effect of lenalidomide that is used for multiple myeloma. The primary efficacy end point of the studies is time to progression (TTP). The interim analysis shows that TTP of the combination group is significantly superior to dexamethasone group. Recent clinical research results show that lenalidomide not only has curative effect on treating MDS and MM, but also on treating myeloma, leukemia, metastatic renal cell carcinoma, solid tumor, idiopathic generalized amyloidosis and systemic bone marrow fibrosis disease with marrow unripe.
Lenalidomide is a new derivative of thalidomide. But its teratogenic toxicity has not found. Its effectiveness is 100 times stronger than thalidomide. According to the result of three clinical trials, lenalidomide is the most effective drug in the treatment of multiple myeloma. More than half of patients can prolong survival time to more than 3 years after taking the drug. In addition, it is also the only effective drugs to treat myelodysplastic syndrome (MDS). Clinical results find that 64% of the patients with MDS need not use blood transfusion after treated by lenalidomide. 
In December 2005, the US Food and Drug Administration (FDA) approved lenalidomide to be used in the treatment of myelodysplastic syndrome (MDS).
In March 2006, the FDA approved lenalidomide that was produced by American Celgene Biological Pharmaceutical Companies to be used in the treatment of multiple myeloma (MM).
On September 23, 2011, the European Medicines Agency (EMA) released information that they have confirmed that the benefits of lenalidomide(trade name: Revlimid) to be used in the treatment of patients group that was approved outweighed the risks. Meanwhile they warned the doctor the risk of the drug to cause new cancer cases. Lenalidomide has been used with dexamethasone to treat adult patients with multiple myeloma that has received at least one treatment. Three new studies show that the incidence of new cancer will be increased in the patients with newly diagnosed multiple myeloma treated by lenalidomide and other combined treatment increased incidence of cancer.

Other products of this supplier

lookchemhot product CAS New CAS